Za­vante hits the fin­ish line, de­clar­ing a piv­otal win for its an­tibi­ot­ic now head­ed (even­tu­al­ly) to the FDA

The team at Za­vante Ther­a­peu­tics had a very sim­ple goal.

Armed with $45 mil­lion in in­vestor back­ing, they took a broad spec­trum an­tibi­ot­ic that’s been used in var­i­ous coun­tries around the world — out­side the US — and put it through a late-stage, head-to-head, non-in­fe­ri­or­i­ty tri­al against a com­bo an­tibi­ot­ic that’s al­ready in use in the US.

And they are claim­ing a win, prep­ping an FDA ap­pli­ca­tion now for a new an­tibi­ot­ic in an in­creas­ing­ly drug-re­sis­tant world as they con­sid­er their op­tions: mar­ket­ing it them­selves or sell­ing it to a play­er in the field.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.